A Prospective, Observational, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Adherence and Efficacy of Tenofovir/Emtricitabine/Rilpivirine (TDF/FTC/RPV) in HIV Post-Exposure Prophylaxis (PEP)
Phase of Trial: Phase IV
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 27 Oct 2017 Status changed from recruiting to completed, according to the final results presented at the 16th European AIDS Conference.
- 27 Oct 2017 Final results presented at the 16th European AIDS Conference.
- 30 Aug 2017 New trial record